Citigroup’s Evolent Health EVH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-201,500
Closed -$6.66M 5701
2023
Q4
$6.66M Buy
+201,500
New +$5.7M ﹤0.01% 1424
2021
Q4
Sell
-50,000
Closed -$1.55M 5896
2021
Q3
$1.55M Buy
+50,000
New +$1.2M ﹤0.01% 2740
2019
Q3
Sell
-100,000
Closed -$795K 7717
2019
Q2
$795K Buy
+100,000
New +$1.18M ﹤0.01% 3922

Other funds holding EVH

Citigroup's EVH Position: Q1 2026 in Review

Citigroup increased its Evolent Health (EVH) stake by 39% in Q1 2026, buying an estimated $722K and bringing the position to 812,095 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2713.

Citigroup first reported a position in EVH in Q2 2015 and has held it in 44 quarters since. The position peaked at $9.18M in Q2 2019. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Citigroup held 812,095 shares of Evolent Health worth $1.85M as of Q1 2026.
  • Citigroup bought 227,630 Evolent Health shares in Q1 2026, an estimated $722K.
  • Evolent Health made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2713 holding.
  • Citigroup first reported a position in Evolent Health in Q2 2015 and has held it in 44 quarters since.
  • Citigroup's Evolent Health position peaked at $9.18M in Q2 2019.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.